Stock Watch: Dam Cracks After A Trickle Of Failed Pandemic Products
Is The Tide Going Out On Biotech’s Contribution To The Pandemic?
Many of the many biotech companies that raised money to develop and repurpose their molecules to address the pandemic have started to unwind those efforts. What will this mean for the sector’s valuation?
